Following a complete response letter rejecting accelerated approval for RP1 in advanced melanoma, IGNYTE trial investigators are urging the FDA to reevaluate the therapy’s robust survival data, just ...

The FDA on Tuesday rejected a skin therapy from Replimune Group, suggesting a hardened stance on drug approvals under new ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...

The FDA has rejected Replimune’s request for approval of RP1, adding the melanoma drug candidate to the list of assets to ...

Replimune Group, Inc. (NASDAQ:REPL) saw its stock nosedive 77% on Tuesday after the company revealed it received a Complete ...

Analysts believe the resignation of a top FDA official could lead to a reversal of the melanoma drug rejection, which was ...

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares. The firm expects a “relatively uneventful” FDA ...

Replimune’s product candidates are designed to comprehensively activate an anti-tumor immune response to a patient’s cancer through the delivery of potent immune activating signals into the ...

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies.

Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune ...

Virtual investor event to be held today at 8:00 am ET WOBURN, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the ...

--Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced it has dosed the first patient in a Phase 1, open ...